deltatrials
Recruiting INTERVENTIONAL NCT07538583

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

A Multicenter, Open-label Study of QRX003 Lotion in Participants With Netherton Syndrome

Sponsor: Quoin Pharmaceuticals

Conditions Netherton Syndrome
Interventions QRX003
Updated 1 time since 2026 Last updated: Apr 20, 2026 Started: Mar 19, 2026 Primary completion: Jan 31, 2027 Completion: Mar 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Netherton Syndrome and is currently actively recruiting participants. Quoin Pharmaceuticals leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Apr 21, 2026 – present · 5 months · daily APIRecruiting

Change History

1 version recorded
Recruiting [daily]

Eligibility Summary

This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.

Contact Information

Sponsor contact:
  • Quoin Pharmaceuticals
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations